地中海贫血 中国就医指南

Thalassemia is a group of inherited hematologic disorders characterized by defective synthesis of one or more globin chains of hemoglobin, leading to imbalanced alpha- and beta-globin production, ineffective erythropoiesis, chronic hemolytic anemia, and systemic iron overload. It arises from mutations—typically deletions or point mutations—in the HBA1/HBA2 (alpha-thalassemia) or HBB (beta-thalassemia) genes on chromosomes 16 and 11, respectively. Pathophysiologically, reduced globin chain synthesis causes unpaired chains to precipitate in red blood cell precursors, triggering apoptosis in the bone marrow (ineffective erythropoiesis) and premature destruction of mature RBCs in the spleen (hemolysis). Compensatory hyperplasia of erythroid precursors expands bone marrow, contributing to skeletal deformities, osteoporosis, and extramedullary hematopoiesis. Chronic anemia induces compensatory cardiac output elevation and tissue hypoxia; repeated transfusions—essential for severe forms—lead to progressive iron deposition in the heart, liver, and endocrine organs, causing cardiomyopathy, cirrhosis, diabetes, and growth failure. Epidemiologically, thalassemia is most prevalent in malaria-endemic regions: Southeast Asia, the Mediterranean basin, Middle East, Indian subcontinent, and Africa. Globally, over 280 million people carry a thalassemia trait; approximately 60,000–100,000 infants are born annually with transfusion-dependent thalassemia (TDT), with China reporting ~10,000–15,000 confirmed cases—concentrated in Guangdong, Guangxi, Hainan, and Yunnan provinces due to historical migration patterns and founder effects. Key risk factors include consanguineous marriage, family history of thalassemia or unexplained anemia, and ethnic ancestry from high-prevalence regions. Prenatal screening and carrier testing significantly reduce incidence where implemented. Quality of life is profoundly impacted: patients with TDT require lifelong monthly transfusions and daily iron chelation therapy, resulting in treatment burden, fatigue, delayed puberty, infertility, psychosocial stress, and reduced educational and occupational participation. Even non-transfusion-dependent thalassemia (NTDT) patients experience chronic complications including thrombosis, pulmonary hypertension, leg ulcers, and gallstones. Psychosocial support, genetic counseling, and multidisciplinary care—including hematology, cardiology, endocrinology, and psychology—are integral to optimizing outcomes. Advances in gene therapy and novel agents like luspatercept offer transformative potential, yet access remains limited in resource-constrained settings.

# 地中海贫血治疗方案与费用明细（血液科）

一、非手术/保守治疗

适用人群：轻型、部分中间型患者，无严重铁过载或器官损伤者。

• •规律输血+去铁治疗：

- 去铁药物：   • 地拉罗司（口服）：3,800–4,500元/盒（30片），月需2–4盒 → 7.6万–18万元/年   • 去铁酮（国产）：1,200–1,800元/盒（100片），月需1–2盒 → 1.4万–4.3万元/年

• •常规监测：血常规、血清铁蛋白、肝肾功能、心脏MRI（铁沉积评估）→ 年检查费约3,200–6,500元

二、根治性治疗（造血干细胞移植）

适用人群：重型β地贫、HLA相合同胞供者、年龄＜14岁、无严重心/肝/肺并发症者。

• •术前检查（配型+器官功能评估）：1.8万–2.6万元
• •移植全流程费用（含预处理、干细胞采集、住院、抗排异及感染防治）：

三、特殊/晚期治疗

• •铁过载相关心衰/肝硬化：联合静脉去铁胺+心功能支持 → 年增费用5万–12万元
• •耐药/复发移植失败者：新型基因疗法（临床试验阶段，限北京协和、上海瑞金等中心）→ 暂不收费，入组免治

四、方案快速选择指南

• •预算＜5万元/年：优选国产去铁酮+规范输血（限中间型）
• •儿童重型患者（＜14岁）：优先评估同胞供者移植（性价比最高）
• •成人重型伴多器官损伤：以去铁+支持治疗为主，暂缓移植